RA Capital Says Better Times Ahead For Healthcare, Biotech As Fund Drops 16% In H1Mark Melin
Halfway through 2016 – one year into the deepest drawdowns in the history of the biotech sector – a major healthcare and life sciences investment fund wants to explain its performance, rated as one of the best by one study.
RA Capital, down -16.4% year to date, says the political rhetoric will subside
After starting the year down more than -21%, but since recovering to down -16.4% as of the end of June, RA Capital Healthcare Fund . . .
This content is exclusively for paying members.
If you are subscribed and having an account error please clear cache and cookies if that does not work email [email protected] or click Chat.